OpenAI has finalised the most structurally novel enterprise AI deal of 2026: a $10bn vehicle anchored by TPG, with 19 investors and a 17.5% guaranteed annual return over five years. The strategy is to make PE portfolios a captive distribution channel. We wrote about the venture’s outline last month; Monday’s confirmation closes the funding question. […]

Blackstone Digital Infrastructure Trust will list on the NYSE under BXDC, targeting newly built data centres leased to hyperscalers. It is the most direct way Wall Street has yet packaged the AI build-out for public investors. For most of the past 18 months, the financial story behind the AI build-out has been a story about […]

After a 30% year-to-date drawdown, Monday’s Q1 results are Palantir’s first chance to argue, not assume, that it does not belong in the broader AI software multiple compression. Until two weeks ago, Palantir was, by some measures, the best-performing large-cap software stock of the AI cycle. It had outpaced Salesforce, Microsoft, Oracle, and Adobe by […]

Three days after suggesting it might target up to $4bn at $40bn, the AI chipmaker has marketed 28 million shares at $115-$125 each, lining the deal up with its February private valuation rather than above it. Cerebras Systems was preparing to seek up to $4bn at a roughly $40bn valuation in its long-awaited initial public […]

The Belgian pharma is buying a two-year-old San Diego biotech for $2bn upfront, the second TCE bet it has placed in months. The thesis: B-cell killers built for cancer can rewire how autoimmune diseases are treated. Candid Therapeutics is two years old. It does not have an approved drug. Its lead programme has been tested […]